menu
    • menu

    Company profile for Therini Bio

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Therini Bio, Inc. is a biotechnology company dedicated to the research and development of novel therapeutics for the treatment of neuroinflammatory diseases due to vascular dysfunction. Our approach will be generally applicable across a range of inflammatory diseases including peripheral indications. The current therapeutic target is based on novel findings by the Akassoglou lab at Gladstone/UCSF that implicate fibrin as a ...
    Therini Bio, Inc. is a biotechnology company dedicated to the research and development of novel therapeutics for the treatment of neuroinflammatory diseases due to vascular dysfunction. Our approach will be generally applicable across a range of inflammatory diseases including peripheral indications. The current therapeutic target is based on novel findings by the Akassoglou lab at Gladstone/UCSF that implicate fibrin as a key driver of neuroinflammation.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Therini BioUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    681 Gateway Blvd., Suite 411 South San Francisco
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.therinibio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Therini Bio Begins Ph 1b Trial of THN391 in Alzheimer’s Disease
    Therini Bio Begins Ph 1b Trial of THN391 in Alzheimer’s Disease

    29 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/29/3123157/0/en/Therini-Bio-Announces-First-Patient-Dosed-in-Phase-1b-Trial-of-THN391-in-Alzheimer-s-Disease.html

    GLOBENEWSWIRE
    29 Jul 2025
    Share Share
    Therini Bio Raises $39M to Advance Neurodegenerative Pipeline
    Therini Bio Raises $39M to Advance Neurodegenerative Pipeline

    14 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/14/3081286/0/en/Therini-Bio-Raises-Additional-39M-Series-A-Financing-to-Advance-Clinical-Development-of-Neurodegenerative-Disease-Pipeline.html

    GLOBENEWSWIRE
    14 May 2025
    Share Share
    Therini Bio reports positive Phase 1a trial results for THN391
    Therini Bio reports positive Phase 1a trial results for THN391

    29 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/29/3070399/0/en/Therini-Bio-Announces-Positive-Phase-1a-Trial-Results-Evaluating-THN391-for-Neurodegenerative-Diseases.html

    GLOBENEWSWIRE
    29 Apr 2025
    Share Share
    Therini Positive Preclinical Data For THN391 In Ocular Diseases
    Therini Positive Preclinical Data For THN391 In Ocular Diseases

    08 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/08/2877868/0/en/Therini-Bio-Announces-Positive-Preclinical-Data-Supporting-the-Development-of-THN391-in-Neurodegenerative-Ocular-Diseases.html

    GLOBENEWSWIRE
    08 May 2024
    Share Share
    Therini Bio Announces Interim Results from the Phase 1 Trial of THN391
    Therini Bio Announces Interim Results from the Phase 1 Trial of THN391

    24 Oct 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/10/24/2765713/0/en/Therini-Bio-Announces-Interim-Results-from-the-Phase-1-Trial-of-THN391-for-the-Potential-Treatment-of-Dementia.html

    GLOBENEWSWIRE
    24 Oct 2023
    Share Share
    Therini Bio Initiates First-In-Human Dosing in Ph 1 Trial of THN391
    Therini Bio Initiates First-In-Human Dosing in Ph 1 Trial of THN391

    15 May 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230515005293/en

    BUSINESSWIRE
    15 May 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search